Compare Hims and Hers Health Inc (HIMS) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance

HIMS trades at $29.71, down 3.04% today, amid ongoing securities class action lawsuits. The stock shows bullish technical signals with strong moving average support and key resistance at $32. Fundamentally, while revenue grew to $2.35B in 2025, the company posted a net loss of -$142M in 2026 with negative profit margins, though it maintains a solid gross margin of 68.4%.

The investment outlook is mixed: technical indicators suggest near-term upside potential toward the $32.17 consensus target, but fundamental weakness and legal overhangs pose significant risks. Analyst sentiment leans cautious with 65% hold ratings, reflecting concerns about profitability and regulatory challenges despite growth prospects.

SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.

Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.